Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah Smith

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Cancers|January 8, 2023
Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)Deborah Smith, Kristy P Robledo, Sonia Yip, et al.
Journal for Immunotherapy of Cancer|June 9, 2021
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trialYoland Antill, Peey-Sei Kok, Kristy Robledo, et al.
EJNMMI Research|March 4, 2022
Target occupancy study and whole-body dosimetry with a MAGL PET ligand [<sup>11</sup>C]PF-06809247 in non-human primatesRyosuke Arakawa, Akihiro Takano, Sangram Nag, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 30, 2008
ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activitiesFeng Liu, Steve Grauer, Cody Kelley, et al.
Journal of Medicinal Chemistry|June 18, 2024
Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M<sub>4</sub> Muscarinic Acetylcholine ReceptorChristopher R Butler, Michael Popiolek, Laura A McAllister, et al.
Genome Medicine|January 11, 2022
Patient-derived xenograft models capture genomic heterogeneity in endometrial cancerVanessa F Bonazzi, Olga Kondrashova, Deborah Smith, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 16, 2009
WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activityJulie A Brennan, Radka Graf, Steven M Grauer, et al.
Cancers|June 2, 2021
Development of a Multi-Institutional Prediction Model for Three-Year Survival Status in Patients with Uterine Leiomyosarcoma (AGOG11-022/QCGC1302 Study)Ka-Yu Tse, Richard Wing-Cheuk Wong, Angel Chao, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Cancers|January 8, 2023
Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)Deborah Smith, Kristy P Robledo, Sonia Yip, et al.
Journal for Immunotherapy of Cancer|June 9, 2021
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trialYoland Antill, Peey-Sei Kok, Kristy Robledo, et al.
EJNMMI Research|March 4, 2022
Target occupancy study and whole-body dosimetry with a MAGL PET ligand [<sup>11</sup>C]PF-06809247 in non-human primatesRyosuke Arakawa, Akihiro Takano, Sangram Nag, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 30, 2008
ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activitiesFeng Liu, Steve Grauer, Cody Kelley, et al.
Journal of Medicinal Chemistry|June 18, 2024
Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M<sub>4</sub> Muscarinic Acetylcholine ReceptorChristopher R Butler, Michael Popiolek, Laura A McAllister, et al.
Genome Medicine|January 11, 2022
Patient-derived xenograft models capture genomic heterogeneity in endometrial cancerVanessa F Bonazzi, Olga Kondrashova, Deborah Smith, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 16, 2009
WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activityJulie A Brennan, Radka Graf, Steven M Grauer, et al.
Cancers|June 2, 2021
Development of a Multi-Institutional Prediction Model for Three-Year Survival Status in Patients with Uterine Leiomyosarcoma (AGOG11-022/QCGC1302 Study)Ka-Yu Tse, Richard Wing-Cheuk Wong, Angel Chao, et al.
Pageof 7